tirzepatide for kidney disease (Zepbound) showed improved function in obese patients with both chronic kidney and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https A Study of Tirzepatide (LY3298176)

Stay Updated Be the first to know when cagrilintide becomes available

Regular monitoring and lifestyle adjustments will help you maintain momentum

"Our study now shows that if you are in a subgroup of long COVID patients who have autoantibodies circulating in your body

Currently doing 10 mg #7 Doing 5mg for amino

While overall AE rates were generally comparable between treatment arms, GI AEs were notably more frequent among participants treated with semaglutide, occurring in 41.9%84.1% of cases, compared with 26.1%63.2% in placebo groups

Until proper studies are conducted, it remains an area of clinical judgment rather than evidence-based medicine